Hong Kong Public Offering Approximately 20.33 Times Oversubscribed(2013-11-07)
Hong Kong Public Offering Approximately 20.33 Times
Oversubscribed
* * *
Final Offer Price Set at HK$3.18per Share
Trading Debuts on 8 November2013
[7 November2013, Hong Kong] PW Medtech Group Limited (“PW Medtech” or the “Company” and, together with its subsidiaries, the “Group”; stock code: 1358), a leading medical device company in China, today announced the Hong Kong Public Offering has received approximately 20.33 times over-subscription. The final offer price is set at HK$3.18per Share, at the mid to high end of the indicative price range. The Company’s shares will commence trading on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) on 8 November 2013(Friday) under the stock code 1358 with board lots of 1,000 shares each.
The International Offering of PW Medtech also recorded over-subscription. The Company offers a total of 400,000,000 Shares under the Global Offering with final offer price set atHK$3.18per Share. The net proceeds from the Global Offering to be received by the Group are estimated to be over HK$1 billion.
Morgan Stanley Asia Limited is the Sole Global Coordinator, Sole Bookrunner, Sole Lead Manager and Sole Sponsor of the Global Offering.
Mr. Lin Junshan, Chairman of PW Medtech, said, “We are delighted to receive an encouraging response from investors towards the Global Offering. PW Medtech’s successful listing on the SEHK marks an important milestone for the Company stepping into international capital market. It not only provides us with an international capital platform, but also equipped us with abundant capital and confidence for long term development. We are committed to seizing the growing market opportunity. The Group will actively broaden and deepen the product portfolio, increase the production capacity and improve the production efficiency, further expand the distribution network and consolidate our leading market position in the industry. We will also continue to seek for merger and acquisition targets in the medical device areas with high growth and high margins, bringing satisfactory returns for the shareholders.”